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(PubMed, MEDLINE, EMBASE, CENTRAL, and 
Web of Science) were screened until March 31, 
2020. Randomized controlled trials or follow ‑up 
studies of RCTs comparing PCI ‑DES and CABG 
in LMD and / or MVD and reporting crude mor‑
tality data at follow ‑up equal to or longer than 5 
years were considered eligible for further anal‑
ysis. The study was approved by the local ethics 
committee. Patient informed consent to partic‑
ipate in the study was not required.
Statistical analysis Pooled odds ratios (ORs) 
and 95% CIs of mortality at reported follow‑
‑up equal to or longer than 5 years were cal‑
culated using a  random effects model with 
the Mantel–Haenszel method. Heterogeneity 
was assessed with the Cochran Q test and pub‑
lication bias by using a funnel plot with logOR 
plotted against standard error.
Results and discussion Six studies1‑6 enroll‑
ing 7312 patients and meeting inclusion crite‑
ria were included. Two studies2,5 were excluded, 
as they recruited patients with previous PCI. 
Detailed study characteristics are presented in 
Supplementary material, Table S1. Three stud‑
ies1,4,6 were focused on LMD. Two studies3,4 ana‑
lyzed MVD only and defined MVD as significant 
stenosis in 2 or more major epicardial vessels 
Introduction Several randomized controlled 
trials (RCTs) compared percutaneous coronary 
intervention (PCI) with coronary artery bypass 
grafting (CABG) for the treatment of coronary 
artery disease (CAD). Coronary artery bypass 
grafting was associated with a long ‑term sur‑
vival benefit as compared with PCI with bare 
metal stent implantation. Subsequent advanc‑
es in interventional cardiology made such con‑
clusions no longer valid. Percutaneous coronary 
intervention with drug ‑eluting stents (PCI ‑DES) 
showed lower rates of major adverse cardiovas‑
cular events. Tested against CABG, it resulted 
in similar safety outcomes but mainly at short‑ 
and mid ‑term follow ‑up. Whether this benefit 
persists at long ‑term follow ‑up (≥5 years) re‑
mains inconclusive. Also, the available evidence 
is conflicting in various clinical scenarios of left 
main disease (LMD) versus multivessel disease 
(MVD). This short communication aimed to as‑
sess the mortality risk following PCI ‑DES com‑
pared with CABG in LMD and MVD, separate‑
ly, based on the results of RCTs with long ‑term 
follow ‑up (≥5 years).
Methods A meta ‑analysis was performed 
in accordance with the  PRISMA (Preferred 
Reporting Items for Systematic Reviews and 
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760 Study or subgroup
PCI-DES CABG OR
M-H, Random, 95% CI
OR
M-H, Random, 95% CIEvents Total Events Total Weight, %
Left main disease
Holm et al (2020), NOBLE 54 592 50 592 21.2 1.09 (073–1.63)
Park et al (2020), PRECOMBAT 42 300 40 300 16.7 1.06 (0.66–1.69)
Stone et al (2019), EXCEL 119 948 89 957 33.9 1.40 (0.64–1.25)
Thuijs et al (2019), SYNTAX Extended Survival 93 357 98 348 28.2 0.90 (0.64–1.25)
Subtotal (95% CI) 2197 2197 100 1.12 (0.91–1.38)
Total events 308 277
Heterogeneity: τ2 = 0.01; χ2 = 4.02; df = 3 (P = 0.26); I2  = 25%
Test for overall effect: Z = 1.04 (P = 0.3)
Multivessel disease 
Farkouh et al (2019), FREEDOM Follow-On 99 478 72 465 36 1.43 (1.02–1.99)
Park et al (2015), BEST 29 438 22 442 12.4 1.35 (0.77–2.40)
Thuijs et al (2019), SYNTAX Extended Survival 151 546 113 549 51.7 1.47 (1.12–1.95)
Subtotal (95% CI) 1462 1456 100 1.44 (1.18–1.76)
Total events 279 207
Heterogeneity: τ2 = 0; χ2 = 0.08; df = 2 (P = 0.96); I2 = 0%
Test for overall effect: Z = 3.57 (P <0.001)
Test for subgroup differences: χ2 = 2.96; df = 1 (P = 0.09); I2 = 66.2% Favors (PCI-DES)                                          Favors (CABG)
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Figure 1 All ‑cause mortality for percutaneous coronary intervention (PCI) with drug ‑eluting stent (DES) implantation and coronary artery bypass grafting (CABG)
 Abbreviations: OR, odds ratio
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high anatomical complexity, the number of pa‑
tients studied in RCTs is low owing to exclusion 
criteria, so no recommendation can be made for 
PCI at the moment. Based on findings from pre‑
vious studies,1,4 it becomes apparent that PCI‑
‑DES may be equally safe in the setting of LMD 
compared with CABG even in a long ‑term per‑
spective. The above findings are also in line with 
a recent meta ‑analysis9 that found no significant 
differences between PCI and CABG regarding 
the all ‑cause mortality risk (relative risk, 1.03; 
95% CI, 0.81–1.32; P = 0.779) or cardiac death 
(relative risk, 1.03; 95% CI, 0.79–1.34; P = 0.817) 
at a mean weighted follow ‑up of 5.5 years. Yet, in 
MVD, CABG confers a long ‑term survival bene‑
fit over PCI ‑DES because of higher rates of com‑
plete revascularization achieved and this has to 
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involving at least 2 separate coronary artery ter‑
ritories excluding LMD. The SYNTAXES (Syn‑
ergy Between PCI with Taxus and Cardiac Sur‑
gery Extended Survival) study5 reported on both 
LMD and 3‑vessel disease (significant stenosis 
in vessels supplying all 3 major epicardial ter‑
ritories excluding LMD), which contributed to 
the pooled analysis in MVD. Studies that con‑
tributed to the analysis of LMD included pa‑
tients with LMD and a history of 2‑ or 3‑vessel 
disease (Supplementary material, Table S1). No 
signs of publication bias were noted (Supple‑
mentary material, Figure S1). In total, 3659 sub‑
jects (50%) underwent PCI ‑DES, and 3653 (50%) 
underwent CABG. Patients were stratified to 2 
subgroups: LMD (4.394 [60%]) and MVD (2.918 
[40%]). In the LMD subgroup, the overall mor‑
tality was 585 / 4394 (13.3%) at a mean weight‑
ed follow ‑up of 6.83 years. There was no differ‑
ence between PCI ‑DES and CABG with respect to 
all ‑cause mortality (OR, 1.12; 95% CI, 0.91–1.38; 
P = 0.3; I2 = 25%) with the corresponding event 
rates of 14% (308 / 2197) and 12.6% (277 / 2197) 
for PCI ‑DES and CABG, respectively (FIGURE 1). In 
the MVD subgroup, the overall mortality was 
486 / 2.918 (16.7%) at a mean weighted follow‑
‑up of 8.01 years. Furthermore, PCI ‑DES was as‑
sociated with a 44% increase of the mortality 
ORs as compared with CABG (OR, 1.44; 95% CI, 
1.18–1.76; P <0.001; I2 = 0%) with the respec‑
tive event rates of 19.1% (279 / 1462) and 14.2% 
(207 / 1.456) for PCI ‑DES and CABG. A differ‑
ence between subgroup interaction (Pint = 0.09) 
did not reach statistical significance.
The current meta ‑analysis is the first to as‑
sess long ‑term (≥5 years) mortality in patients 
undergoing PCI ‑DES compared with those un‑
dergoing CABG. Our subgroup analysis showed 
a relative 44% increase in mortality ORs for PCI‑
‑DES in the setting of MVD and equal safety in 
LMD. Together with a subgroup interaction of 
borderline significance, the meta ‑analysis dem‑
onstrated different risk profiles of patients with 
LMD or MVD, resulting from less or more dif‑
fuse CAD. Indeed, mortality in the PCI ‑DES arm 
was 14% versus 19.1% depending on the extent 
of CAD (LMD versus MVD). The mortality rates 
following CABG remained merely similar (12.6% 
vs 14.2%). Completeness of revascularization, 
which is less frequently achieved with PCI ‑DES 
in MVD, must have also played some role. An‑
other potentially relevant issue not addressed 
in neither RCT yet, is a medical history of PCI; 
a recent study showed less favorable outcomes 
in patients who underwent PCI prior to CABG.7 
Lastly, coronary complexity should be also con‑
sidered; in fact, current European Society of 
Cardiology / European Association for Cardio‑
‑Thoracic Surgery guidelines8 indicate that PCI is 
an appropriate alternative to CABG in LMD and 
low ‑to ‑intermediate anatomical complexity. On 
the other hand, among patients with LMD and 
